When they hooked up with CD-2, the decoys prevented the real LFA-3 from binding to and activating the T cells.
FORBES: Skin Deep
2.
Biogen scientists crafted decoys by cloning and attaching the binding site of LFA-3 onto the Y-shaped tail of a harmless antibody.
FORBES: Skin Deep
3.
In the early 1990s, dermatologist Kevin Cooper, then at the University of Michigan, observed that the binding of CD-2 to LFA-3 set off psoriasis' chain reaction.